Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722497 | 0.87 | CYP11B1 (0.53) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL10726790 | 0.84 | RAB9A (0.52) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL10723314 | 0.83 | RAB9A (0.52) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL8178162 | 0.83 | CYP11B1 (0.56) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL10130808 | 0.82 | CYP11B1 (0.52) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL13514078 | 0.82 | CYP11B1 (0.52) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL10726975 | 0.82 | RAB9A (0.55) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL10722341 | 0.82 | RAB9A (0.55) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL10726938 | 0.82 | RAB9A (0.55) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 | |
| SCHEMBL10723854 | 0.82 | RAB9A (0.55) | CYP11B1CYP11B2HPGDSKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9751897-B1 | Derivatives of Bodipy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170233414-A1 | DERIVATIVES OF BODIPY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016098028-A1 | END CAPPED NUCLEIC ACID MOLECULES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2007119600-A1 | CARBAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-4659503-A | Pyridylthiophenes | Merck Patent Gesellschaft Mit Beschrankter Huftung (DE) | 1987-04-21 | — | — | US | disclosed |
| EP-0146862-A2 | Pyridyl thiophenes | MERCK PATENT GmbH (DE) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | CYP11B1 49/4885CYP11B2 85/4885HPGDS 703/4885 |
| US-20170233414-A1 | DERIVATIVES OF BODIPY | NPC1L1, NPC1, ABCB4 | CYP11B1 1030/4885CYP11B2 1380/4885HPGDS 1995/4885 |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | CYP11B1 4873/4885CYP11B2 4879/4885HPGDS 4001/4885 |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | CYP11B1 4873/4885CYP11B2 4879/4885HPGDS 4001/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CYP11B1 49/4885CYP11B2 85/4885HPGDS 703/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | CYP11B1 58/4885CYP11B2 64/4885HPGDS 1151/4885 |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NSUN2, NSUN3, RNGTT | CYP11B1 4868/4885CYP11B2 4871/4885HPGDS 4212/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | CYP11B1 67/4885CYP11B2 86/4885HPGDS 212/4885 |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | CYP11B1 4880/4885CYP11B2 4881/4885HPGDS 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.